As the genomic era in oncology unfolds, the development of new therapeutics increasingly will involve targeting a range of mutations simultaneously, requiring a "next-generation clinical trials system" to match the advances that technology is delivering.
Two large clinical trials are expected to define the impact that employing genomic tests in treatment decisions has on survival outcomes, according to Martine J. Piccart, MD, PhD.
Oncology leaders are bracing for a host of changes in the healthcare system, not only as a result of the recently upheld insurance reform legislation but also because of continued pressure to control the ever-rising cost of cancer care.
Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the field of psycho-oncology.
Burnout is described as a syndrome of "emotional exhaustion, depersonalization, and feelings of low personal accomplishment," and is an increasingly problematic condition among physicians for a multitude of reasons.
Hope S. Rugo, MD, at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the standard for front-line chemotherapy in patients with breast cancer.
An interview with Debu Tripathy, MD, summarizing noteworthy results from the 2012 ASCO Annual Meeting and SABCS, including clinical studies in local, adjuvant, and metastatic breast cancer therapies.
Dr. Debu Tripathy, from the USC Norris Comprehensive Cancer Center, Discusses Breast Cancer Prevention
Recognition of breast cancer subtypes and research into their underlying biologies is driving the development of new therapies.
Dr. Julie Gralow, from the Seattle Cancer Care Alliance, on Adjuvant Bisphosphonates for Breast Cancer
Next-generation immunotherapy in breast cancer treatment is an active field of scientific exploration with the potential to yield a vaccine.
Dr. Daniel Osman, the program chair for the Miami Breast Cancer Conference, Discusses the 29th Annual Meeting
Technological advances in genomics have prompted a "sea change" in breast cancer drug development and treatment.
The choice of breast-conserving surgery over mastectomy is often based on fear of recurrence and death rather than clinical evidence.
Pictures from the Annual Miami Breast Cancer Conference, at the Fontainebleau Miami Beach hotel, in Florida.
Debu Tripathy, MD, culled the highlights from abstracts presented in 2011 at the ASCO annual meeting in Chicago, Illinois, and at the CCTR-AARC SABCS in Texas.
The impact of molecular and genomic advancements on the treatment of patients with breast cancer will be among the prime topics of discussion.
As the Miami Breast Cancer Conference enters its 29th year, Osman continues to organize the gathering and pack the 4-day meeting with faculty speakers.
In this podcast, Maisam Fazel, FRCS, MS, MB BChir, discusses his research into a checklist for breast cancer surgeons.
Dr. Daniel Osman, director of the Miami Breast Cancer Conference, on Designing the Program for the MBCC
Maisam Fazel, FRCS, MS, MB BChir, of Imperial College Healthcare NHS Trust in the United Kingdom on Trends in Surgical Training
As the number of breast cancer survivors grows, so does the emphasis on establishing individualized survivorship plans
Preoperative neoadjuvant systemic therapy can be valuable for patients even if they do not achieve a pathologic complete response
Preoperative neoadjuvant systemic therapy can be valuable for patients even if they do not achieve a pathologic complete response
With thousands of clinical trials in play, many oncology specialists are reluctant to embrace findings from newly-released studies
Should genomic profiles be used routinely to determine which breast cancer patients receive adjuvant chemotherapy
Personalized treatment in oncology is a popular concept these days, but the goal remains elusive
It is time to rethink the way oncologists in the United States are treating ductal carcinoma in situ
The addition of sorafenib to capecitabine as a first-line therapy for patients with advanced breast cancer
Daniel A. Osman, MD, Founder and Course Director of the Miami Breast Cancer Conference Discusses Methods for Detecting Malignant Conditions in Breast Cancer